Skip to content

Oral Risperidone and Clonidine in children with tics

To compare the efficacy of oral Risperidone and Clonidine in children with tics aged 6-18 years: a single blind randomized controlled trial - RAC-TIC Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026505
Enrollment
40
Registered
2020-07-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G968- Other specified disorders of central nervous system

Interventions

Intervention1: Arm A oral Risperidone: 1. 2 weeks placebo phase followed by 8 weeks intervention phase 2. If the patient responds to the placebo trial, than he will be excluded from enrolment in the s

Sponsors

All India Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Aged 6 to 18 years and weight of at least 15 kg 2. Has motor and/or vocal tics and requiring medication 3. If female, not sexually active 4. Medication free or adequate washout period (2 weeks prior to enrollment) of psychoactive drugs

Exclusion criteria

Exclusion criteria: 1. Any other co-morbid neuropsychiatric problems other than ADHD and OCD 2. Prior use of risperidone or clonidine for more than 2 weeks in last one month 3. Seizure during the past 6 months 4. History or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments during the trial including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, hematologic or immunologic disease as determined by the clinical judgment of the investigator 5. Current suicidal or homicidal risk 6. Dependent on other substances, with the exception of nicotine or caffeine 7. Females who are found to be sexually active and are not willing to use oral contraceptives

Design outcomes

Primary

MeasureTime frame
Change in YGTSS score from baseline after 8 weeks of drug treatment in both armsTimepoint: 8 weeks

Secondary

MeasureTime frame
a. Yale-Brown obsessive compulsive scale (Y-BOCS)Timepoint: 8 weeks;b. Connorâ??s parent rating scale-revised, 3rd edition (CPRS-R)Timepoint: 8 weeks;c. Tic-CGI-S scoreTimepoint: 8 weeks;d. TS-CGI-S scoreTimepoint: 8 weeks;e. OCD-CGI-S scoreTimepoint: 8 weeks;f. MOVES scoreTimepoint: 8 weeks;g. PUTS scoreTimepoint: 8 weeks;h. Simpson Angus rating scale-EPSTimepoint: 8 weeks;i. Childhood Depression Rating Scale-revised (CDRS-R)Timepoint: 8 weeks

Countries

India

Contacts

Public ContactDr Indar Kumar Sharawat

All India Institute of Medical Sciences, Rishikesh

sherawatdrindar@gmail.com09560182301

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026